TrovaGene
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch TrovaGene and buy or sell other stocks, ETFs, and their options commission-free!About TROV
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
CEOMark Erlander, PhD
CEOMark Erlander, PhD
Employees33
Employees33
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1999
Founded1999
Employees33
Employees33
TROV Key Statistics
Market cap79.84M
Market cap79.84M
Price-Earnings ratio-3.62
Price-Earnings ratio-3.62
Dividend yield—
Dividend yield—
Average volume1.16M
Average volume1.16M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$4.99
52 Week high$4.99
52 Week low$1.90
52 Week low$1.90
Stock Snapshot
With a market cap of 79.84M, TrovaGene(TROV) trades at $1.19. The stock has a price-to-earnings ratio of -3.62.
On 2025-12-31, TrovaGene(TROV) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for TrovaGene(TROV) stock has reached 0, versus its average volume of 1.16M.
Over the past 52 weeks, TrovaGene(TROV) stock has traded between a high of $4.99 and a low of $1.90.
Over the past 52 weeks, TrovaGene(TROV) stock has traded between a high of $4.99 and a low of $1.90.
People also own
Based on the portfolios of people who own TROV. This list is generated using Robinhood data, and it’s not a recommendation.